Florbetapir "Imaging to Autopsy" Study Awarded Alzheimer's Association's 2011 de Leon Prize in Neuroimaging

- de Leon Prize is Top Industry Award in the Field -

INDIANAPOLIS, July 18, 2011 /PRNewswire/ -- The study, "Use of Florbetapir-PET for Imaging beta-amyloid Pathology," published in the Jan. 19, 2011 issue of the Journal of the American Medical Association, has been selected by the Alzheimer's Association as the winner of the 2011 de Leon Prize in Neuroimaging for the "Best Paper" in human neuroimaging, in the Senior Scientist category. The award was presented Saturday, July 16, 2011, to Chris Clark, M.D., co-author of the paper and medical director at Avid Radiopharmaceuticals, a wholly-owned subsidiary of Eli Lilly and Co., during the Alzheimer's Imaging Consortium (AIC), in Paris, France. The AIC was a preconference to the Alzheimer's Association International Conference 2011 (AAIC 2011), held from July 17-21, 2011.

The paper reported the results of a Phase III "Imaging to Autopsy" study that was designed to determine if florbetapir positron emission tomographic (PET) imaging performed during life predicted the presence or absence of beta-amyloid plaques in the brain at autopsy. The ability to identify and quantify brain beta-amyloid potentially could enable a negative florbetapir-PET scan to rule out amyloid pathology in the brain.

"It is an honor to receive this award as it represents further validation of the importance of the study and recognition of the impact the paper may have on the future of neuroimaging of Alzheimer's disease pathology," said Clark. "Helping to lead this collaborative study was a life changing event for me and I am pleased to be able to donate the prize earnings back to the Alzheimer's Association to support their efforts."

About Florbetapir F18

Florbetapir F18 injection is a molecular PET-imaging agent under investigation for the detection of beta-amyloid plaque in the brains of living patients. Florbetapir F18 was the first beta-amyloid imaging compound to enter multi-center, investigational new drug (IND) clinical studies in the U.S. Florbetapir F18 is neither a screener for asymptomatic patients, nor a standalone diagnostic for Alzheimer's disease.

About the de Leon Prize in Neuroimaging

The de Leon Prize in Neuroimaging is presented by the Neuroimaging Professional Interest Area (NPIA) of ISTAART, the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment.

NPIA awards two prizes annually for the best papers published in any peer reviewed journal, one in the Senior Scientist category and one in the New Investigator category. Both awards carry unrestricted prizes and are presented during the AIC, a preconference to the AAIC 2011.

The topic of the papers must relate to in-vivo neuroimaging of a neurodegenerative process. The nomination for the "Best Paper" award must be for papers published or in press galley proof, in the period between July 1, 2010 and June 30, 2011.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

This press release contains forward-looking statements about florbetapir F18 injection for use as a molecular imaging tool for the detection of beta-amyloid plaque in the brains of living patients. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that this compound will be approved by the relevant regulatory authorities or be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)

P-LLY

SOURCE Eli Lilly and Company

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.